PT-141 research: bremelanotide in the published literature
A melanocortin receptor agonist with a real FDA approval and a specific indication — and a research history that is broader than the approval itself.
TL;DR
- PT-141 is the development name for bremelanotide, a melanocortin receptor agonist.
- The branded version, Vyleesi, is FDA-approved for hypoactive sexual desire disorder in premenopausal women.
- Earlier research studied it for erectile dysfunction in men. Most modern trial data is in women.
What it is
PT-141 is the research-stage name for bremelanotide. Bremelanotide is a synthetic peptide that activates melanocortin receptors in the brain. It is FDA-approved under the brand name Vyleesi for hypoactive sexual desire disorder (HSDD — in plain English: persistent low desire that causes distress) in premenopausal women (Kingsberg et al., Obstetrics & Gynecology, 2019).
How it works
The cleanest analogy: most ED medications act on plumbing. PT-141 acts on the wiring.
Bremelanotide binds to melanocortin-4 receptors in the central nervous system. The signal influences brain pathways involved in sexual arousal and desire. That is a different mechanism from PDE5 inhibitors, which improve blood flow but do not address desire (Pfaus et al., Journal of Sexual Medicine, 2016).
Because the action is central, the effect is on desire itself rather than on physical response alone. About 1 in 4 women in the published trials had a clinically meaningful response on the desire score used in the studies.
Who asks about it
People usually arrive at PT-141 after running into the limits of PDE5 inhibitors or after reading about Vyleesi. The follow-up question is what the research base looks like beyond the FDA-approved indication. That is what this post tries to answer.
What the research says
The pivotal trials for women — the RECONNECT studies — supported the FDA approval of Vyleesi in 2019 (Kingsberg et al., 2019). The earlier development arc included studies in men with erectile dysfunction. The drug program eventually focused on women’s sexual desire, where the central mechanism appeared most differentiated.
The honest qualifier: long-term outcome data in real-world clinical use is still building, and the compounded version used in non-Vyleesi settings does not have the same trial backing.
What to know before considering it
PT-141 requires a prescription and a licensed clinician evaluation. Side effects in the published literature include nausea, flushing, transient blood pressure increases, and headache. Patients with uncontrolled high blood pressure or known cardiovascular disease are usually not candidates.
The Halftime POV
PT-141 is one of the more interesting peptides in the sexual health category because the mechanism is genuinely different from anything else in clinical use. It is not a replacement for PDE5 inhibitors. It addresses a different question. We try to be clear about which question it actually answers.
Related reading:
- PT-141 (bremelanotide): how melanocortin signaling affects desire
- How PT-141 signals desire through melanocortin receptors
- Bremelanotide is FDA-approved for women: what Vyleesi actually treats
FAQ
Q: What has PT-141 been studied for? A: PT-141, also called bremelanotide, has been studied for sexual desire disorders in women and for erectile function in men. The largest trials supported FDA approval of Vyleesi for hypoactive sexual desire disorder in premenopausal women.
Q: Is PT-141 FDA-approved? A: Bremelanotide under the brand name Vyleesi is FDA-approved for one specific indication: hypoactive sexual desire disorder in premenopausal women. Compounded PT-141 used outside that indication is not FDA-approved.
Q: Does PT-141 work in men? A: Earlier research studied PT-141 for erectile dysfunction in men. Subsequent development for women’s sexual desire moved further. Use in men exists in compounded form but is not an FDA-approved indication.
Disclaimer
This article is educational and is not medical advice. Compounded medications are not FDA-approved. Clinical outcomes depend on individual factors and require physician evaluation. Results vary. Halftime Health is launching soon — join the waitlist to get updates.
Get updates
Halftime Health is launching soon. We’ll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we’ll email you when we’re live.
Sources
- Kingsberg SA, et al. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. Obstetrics & Gynecology, 2019.
- Pfaus J, Giuliano F, Gelez H. Bremelanotide: an overview of preclinical CNS effects on female sexual function. Journal of Sexual Medicine, 2016.
